Simpson Thacher & Barlett Represented Underwriters In $5 Billion Debt Offering by AstraZeneca
The net proceeds to be used for general corporate purposes would include the refinancing of existing indebtedness
trueasdfstory
Simpson Thacher & Barlett Represented Underwriters In $5 Billion Debt Offering by AstraZeneca The net proceeds to be used for general corporate purposes would include the refinancing of existing indebtedness Simpson Thacher & Barlett has represented the underwriters in a US-registered public offering of $5 billion senior notes with maturities ranging between three and ten...
Simpson Thacher & Barlett Represented Underwriters In $5 Billion Debt Offering by AstraZeneca
The net proceeds to be used for general corporate purposes would include the refinancing of existing indebtedness
Simpson Thacher & Barlett has represented the underwriters in a US-registered public offering of $5 billion senior notes with maturities ranging between three and ten years by AstraZeneca Finance LLC, a wholly owned subsidiary of AstraZeneca PLC.
AstraZeneca is a global, science-led biopharmaceutical company. It focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology.
The Simpson Thacher & Barlett team included Mark Brod, Joann Kim and Rob Bloomer (capital markets); Jonathan Cantor (tax); Vanessa Burrows and Nawa Lodin (healthcare regulatory); Bobbie Burrows and Alysha Sekhon (IP); and Jennie Getsin (Finra and Blue Sky).